Developing a drug from discovery through to product launch is a complex process that can unfold along various development paths. Each path may involve different players, such as academia, venture capital, start-up companies, and pharmaceutical companies. Each path has its advantages and disadvantages.
Different routes include spin-offs from academia, academic-industry partnerships, licensing of technology, contract research organizations (CROs), and public funding. How do you choose which path is right for your invention? How do you keep your options open?
The most obvious route is probably spinning off your IP into a start-up and finding funding to develop your invention further. In many cases a start-up is a key vehicle between academic discovery and patient. Again, there are different considerations in terms of business models including licensing, mergers, acquisitions and IPO.
During this program our speakers will share their insights in the different paths there are from discovery to patient. In the first section of the program, we will discuss the choices that need to be made early on, while in the second part we will focus in on considerations for start-ups, as that is the most travelled route.
This program specifically targets early innovators and start-ups looking to bring their drug to patients. Where local considerations are essential, our speakers will focus in on the Dutch life sciences ecosystem, while most insights will have universal relevance.